Industry's perception of presenting pharmacoeconomic models to managed care organizations.
نویسندگان
چکیده
BACKGROUND Previous research has shown that pharmacoeconomic (PE) data are considered important but may not be optimally utilized by decision makers. No research has compared the effectiveness of different types of PE models. OBJECTIVES The purpose of this study was to examine the perceived value and understanding of PE models among decision makers in managed care organizations. The perspective of this study was from research scientists working in the pharmaceutical industry who present PE models to managed care clients. The study objectives were to (1) examine what types of models are best received by decision makers, (2) investigate the barriers to using PE models, and (3) recommend methods for improving PE models. METHODS A telephone survey of 39 items was conducted with 20 PE research scientists from various U.S. pharmaceutical and biotechnology companies. Topics addressed included factors contributing to how well PE models are received, barriers to using PE models, and recommendations for improving PE models. RESULTS Models have an impact on health policy decision making. Nineteen of 20 respondents had at least one experience where a PE model played a role in optimizing the formulary positioning of a product. No single model format (e.g., decision analytic tools, spreadsheet analyses, Markov models, multivariate regression models) was regarded as the most effective model type. Although 7 of 20 respondents said simple spreadsheet models were most effective, well-designed, scientifically sound regression models were also reported to be very effective. CONCLUSIONS The respondents commonly used models to share PE information, which was said to play a role in making health policy decisions by decision makers in managed care. There was no consensus regarding the type of model that was most effective. Study participants indicated that a variety of model designs are effective, ranging from simple spreadsheet models to multivariate regression models. Recommendations for improving PE models include (1) producing scientifically sound models, (2) customizing models where possible, (3) making models transparent, (4) making models user friendly, and (5) involving a nonbiased third party for model development.
منابع مشابه
Considerations for implementing a new combination vaccine into managed care.
BACKGROUND The control and elimination of several deadly childhood diseases are a result of extensive vaccination efforts made by pediatricians, family practitioners, public health providers, and health outreach systems. Managed care can assist this effort through facilitating the delivery of affordable quality healthcare to patients. OBJECTIVE To describe the considerations made by managed c...
متن کاملThe role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines.
OBJECTIVE To review evidence-based medicine (EBM) in the context of pharmacoeconomic (PE) decision making by health care organizations. SUMMARY Pharmacoeconomics involves processes similar to EBM, but it deals with decisions on the population rather than the patient level. The overall goal of PE is to provide the most efficient use of resources, taking into account both the cost and the value...
متن کاملEconomic benefits and costs associated with target vaccinations.
BACKGROUND As a therapeutic class, vaccines are generally considered to be the health care intervention that provides the best value. In the pharmacoeconomic study of vaccines, it is common for researchers to conduct their analyses from a societal perspective, including direct medical costs as well as indirect costs. OBJECTIVE To discuss the data elements of pharmacoeconomic analyses of vacci...
متن کاملDo decision-analytic models identify cost-effective treatments? A retrospective look at helicobacter pylori eradication.
BACKGROUND Pharmacoeconomic models of Helicobacter (H) pylori eradication have been frequently cited but never validated. OBJECTIVE Examine retrospectively whether H pylori pharmacoeconomic models direct decision makers to cost-effective therapeutic choices. METHODS We first replicated and then validated 2 models, replacing model assumptions with empirical data from a multipayer claims data...
متن کاملA pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America.
The escalating role played by managed care organizations in the health-care system is reflected in the increased demand for cost-effectiveness analyses (CEAs) to assess the balance between economic impact and clinical efficacy. For example, the high incidence and costs associated with colorectal cancer in Latin America calls for a comprehensive economic evaluation to ensure appropriate allocati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of managed care pharmacy : JMCP
دوره 9 2 شماره
صفحات -
تاریخ انتشار 2003